In support of this, clinical trial studies show HER3 upregulation is associated with poor prognosis in OC, which serves as a clinical marker of tumor development, and HER3 expression is induced in response to current chemotherapeutics agents [186,187]. The gene discussed is ERBB3; the disease is neoplasm.